WallStreetZenWallStreetZen

NASDAQ: SPRY
Ars Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for SPRY

Based on 5 analysts offering 12 month price targets for Ars Pharmaceuticals Inc.
Min Forecast
$1.80-78.56%
Avg Forecast
$7.06-15.9%
Max Forecast
$14.00+66.77%

Should I buy or sell SPRY stock?

Based on 7 analysts offering ratings for Ars Pharmaceuticals Inc.
Hold
Strong Buy
0 analysts 0%
Buy
2 analysts 28.57%
Hold
5 analysts 71.43%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their SPRY stock forecasts and price targets.

SPRY stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Wedbush
Bottom 27%
27
BuyInitiates Coverage On$10.00+19.12%2023-01-31
SVB Leerink
Bottom 3%
3
BuyInitiates Coverage On$14.00+66.77%2022-12-13
Goldman Sachs
Bottom 8%
8
HoldDowngrades$3.50-58.31%2022-04-04
JonesTrading
Bottom 9%
9
HoldDowngradesN/AN/A2022-04-01
SVB Leerink
Bottom 1%
1
HoldDowngrades$1.80-78.56%2022-04-01
HC Wainwright & Co.
Bottom 19%
19
HoldDowngradesN/AN/A2022-04-01
Stifel Nicolaus
Bottom 8%
8
HoldDowngrades$6.00-28.53%2022-04-01

1 of 1

Forecast return on equity

Is SPRY forecast to generate an efficient return?
Company
N/A
Industry
-0.1%
Market
28.88%

Forecast return on assets

Is SPRY forecast to generate an efficient return on assets?
Company
N/A
Industry
0.01%

SPRY earnings per share forecast

What is SPRY's earnings per share in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
-$2.09
Avg 2 year Forecast
-$1.69
Avg 3 year Forecast
-$0.72

SPRY revenue forecast

What is SPRY's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$31.3M
Avg 2 year Forecast
$87.5M
Avg 3 year Forecast
$77.5M

SPRY vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
SPRY$8.40$7.06-15.90%Hold
CRBU$4.88$29.80+510.66%Buy
STRO$5.11$21.00+310.96%Strong Buy
RANI$6.33$21.67+242.29%Strong Buy
AVIR$3.50$6.00+71.43%Sell
View Top Biotech Stocks

Ars Pharmaceuticals Stock Forecast FAQ

Is Ars Pharmaceuticals Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 7 Wall Street analysts covering (NASDAQ: SPRY) stock is to Hold SPRY stock.

Out of 7 analysts, 0 (0%) are recommending SPRY as a Strong Buy, 2 (28.57%) are recommending SPRY as a Buy, 5 (71.43%) are recommending SPRY as a Hold, 0 (0%) are recommending SPRY as a Sell, and 0 (0%) are recommending SPRY as a Strong Sell.

If you're new to stock investing, here's how to buy Ars Pharmaceuticals stock.

What is SPRY's earnings growth forecast for 2023-2025?

(NASDAQ: SPRY) Ars Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.24%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 19.48%.

Ars Pharmaceuticals's earnings in 2023 is -$85,384,000.On average, 1 Wall Street analyst forecast SPRY's earnings for 2023 to be -$75,361,926, with the lowest SPRY earnings forecast at -$75,361,926, and the highest SPRY earnings forecast at -$75,361,926. On average, 1 Wall Street analyst forecast SPRY's earnings for 2024 to be -$60,938,591, with the lowest SPRY earnings forecast at -$60,938,591, and the highest SPRY earnings forecast at -$60,938,591.

In 2025, SPRY is forecast to generate -$25,962,003 in earnings, with the lowest earnings forecast at -$25,962,003 and the highest earnings forecast at -$25,962,003.

What is SPRY's revenue growth forecast for 2024-2026?

(NASDAQ: SPRY) Ars Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 40.95%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 8.76%.

Ars Pharmaceuticals's revenue in 2023 is $0.On average, 1 Wall Street analysts forecast SPRY's revenue for 2024 to be $1,126,823,063, with the lowest SPRY revenue forecast at $1,126,823,063, and the highest SPRY revenue forecast at $1,126,823,063. On average, 1 Wall Street analysts forecast SPRY's revenue for 2025 to be $3,155,104,575, with the lowest SPRY revenue forecast at $3,155,104,575, and the highest SPRY revenue forecast at $3,155,104,575.

In 2026, SPRY is forecast to generate $2,794,521,195 in revenue, with the lowest revenue forecast at $2,794,521,195 and the highest revenue forecast at $2,794,521,195.

What is SPRY's forecast return on assets (ROA) for 2023-2026?

(NASDAQ: SPRY) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 0.01%.

What is SPRY's Price Target?

According to 5 Wall Street analysts that have issued a 1 year SPRY price target, the average SPRY price target is $7.06, with the highest SPRY stock price forecast at $14.00 and the lowest SPRY stock price forecast at $1.80.

On average, Wall Street analysts predict that Ars Pharmaceuticals's share price could fall to $7.06 by Jan 31, 2024. The average Ars Pharmaceuticals stock price prediction forecasts a potential downside of 15.9% from the current SPRY share price of $8.40.

What is SPRY's Earnings Per Share (EPS) forecast for 2023-2025?

(NASDAQ: SPRY) Ars Pharmaceuticals's current Earnings Per Share (EPS) is -$2.42. On average, analysts forecast that SPRY's EPS will be -$2.09 for 2023, with the lowest EPS forecast at -$2.09, and the highest EPS forecast at -$2.09. On average, analysts forecast that SPRY's EPS will be -$1.69 for 2024, with the lowest EPS forecast at -$1.69, and the highest EPS forecast at -$1.69. In 2025, SPRY's EPS is forecast to hit -$0.72 (min: -$0.72, max: -$0.72).

What is SPRY's forecast return on equity (ROE) for 2023-2026?

(NASDAQ: SPRY) forecast ROE is N/A, which is considered weak.
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTube
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.